The Gotthardt Healthgroup is based in Heidelberg and was founded in July 2015. The company focuses on improving the discovery and management of diseases, which place great burdens on individuals and society, on optimizing drug delivery, on efficiencies gains in clinical studies and on better tools for consumers to shape their own health.
Sustainability is a top priority at the Gotthardt Healthgroup. Therefore, the holding company follows the highest ethical standards and fully complies with the German and European data protection regulations. The Gotthardt Healthgroup always strives for excellent implementation in order to seamlessly integrate medical evidence into the respective workflows and thought processes for maximum impact. The Gotthardt Healthgroup comprises of the Gotthardt Healthgroup AG and the Mediteo GmbH.
About the Gotthardt Healthgroup AG
“Medical Evidence to Action” is the guiding principle of the Gotthardt Healthgroup AG (GHG), and its digital solutions and services for the healthcare industry. According to the company’s mission, these digital solutions and services positively and sustainably support the workflows, processes and behaviors of participants in the healthcare market and provide meaningful insights into current treatment methods. An example of these solutions is the GHG Praxisdienst, which provides physicians in private practice with valuable information about clinical trials and which patients and families will benefit from these new approaches. The GHG Praxisdienst is being developed by the Gotthardt Healthgroup AG.
When confronted with the many challenges of everyday life, it can be difficult for patients to keep an overview of, and adhere to, their medication regime. Mediteo GmbH is a digital health start-up that supports patients to manage their medication. Developed by doctors, the Mediteo app allows users to easily and securely manage their medication and provides regular and timely notifications when it’s time to take their medicine. The Mediteo app helps its users to better integrate their personal therapy plan into their everyday life and to keep it safe. This allows users to take control of their therapy in a simple and intuitive way, and Mediteo also informs its users about the correct use of the medication and what side effects and interactions can occur. With that, Mediteo contributes to improved drug therapy safety. For more information, visit www.mediteo.com.
Prof. Dr. Daniel Gotthardt
Chief Executive Officer
Prof. Dr. med. Daniel Gotthardt is CEO of Gotthardt Healthgroup AG, managing director of Mediteo GmbH and also deputy chairman of the supervisory board of CompuGroup Medical SE. Prior he served as Senior Physician at the University Hospital Heidelberg, where he had been working for 13 years.